PhotoCure - Metvix® application Switzerland
PhotoCure ASA announced today the submission of a marketing authorisation application to the Swiss authorities for Metvix® PDT (Photodynamic Therapy) for the treatment of basal cell carcinoma (BCC), and actinic keratosis (AK). Internationally recognised University hospitals in Switzerland have already stated their interest in starting treatment with Metvix® PDT.
Metvix® PDT is already launched in Sweden and approved in 13 additional European countries while applications are pending in Australia, New Zealand and the US. PhotoCure has licensed the rights to promote and sell Metvix® PDT outside the Nordic area to Galderma S.A.